Company Search:
Advanced Search
Sponsored Links
Genmab A/S Company Snapshot
Genmab A/S operates in the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Genmab A/S with three other miscellaneous service companies in Europe: AddLife AB of Sweden (2015 sales of 1.06 billion Swedish Kronor [US$118.68 million] of which 98% was LabTech), Bavarian Nordic AS (1.02 billion Danish Kroner [US$146.04 million] ), and Pharma Mar SA which is based in Spain (193.82 million Euro [US$206.19 million] of which 65% was Biotech Sector).

Sales Analysis. Genmab A/S reported sales of 1.13 billion Danish Kroner (US$162.14 million) for the year ending December of 2015. This represents an increase of 33.2% versus 2014, when the company's sales were 850.39 million Danish Kroner. This was the fourth straight year of sales growth at Genmab A/S.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Genmab A/S
  Stock Performance Chart for Genmab A/S
  Stock Data: Recent Stock Performance:
  Current Price (1/13/2017): 1,286.00
(Figures in Danish Kroner)
1 Week -1.1%   13 Weeks 12.9%  
4 Weeks 14.5%   52 Weeks 57.0%  
Genmab A/S Key Data:
  Ticker: GEN Country: Denmark
  Exchanges: CPH Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2015 Sales 1,133,041,000
(Year Ending Jan 2016).
Employees: 186
  Currency: Danish Kroner Market Cap: 77,479,695,742
  Fiscal Yr Ends: December Shares Outstanding: 60,248,597
  Share Type: Stammaktie Closely Held Shares: 2,834,715
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.